Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

William Kvasnicka

Physician Assistant, Medical Chicago, IL Physician Assistant

NPI 1801225024 CMS profile 10449928

3501 N Halsted St, Chicago, IL 60657

Open in the dashboard

General payments

$19,242

564 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Kvasnicka of Chicago, IL is reported in the CMS Open Payments database as having received $19,242 across 564 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,765 130
2024 General $2,266 106
2023 General $4,178 127
2022 General $3,421 116
2021 General $3,613 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Kvasnicka
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to William Kvasnicka were reported at $5,765. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year William Kvasnicka Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,613 $156 $41–$563 $132
2022 $3,421 $185 $55–$649 $149
2023 $4,178 $199 $58–$717 $160
2024 $2,266 $206 $62–$740 $164
2025 $5,765 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $7,968 173 payments
  2. ViiV Healthcare Company $5,192 208 payments
  3. Janssen Scientific Affairs, LLC $1,160 1 payment
  4. Merck Sharp & Dohme Corporation $866 36 payments
  5. Janssen Products, LP $850 3 payments
  6. Janssen Biotech, Inc. $493 28 payments
  7. AbbVie, Inc. $352 14 payments
  8. Novo Nordisk Inc $334 11 payments
  9. McKesson Medical-Surgical, Inc. $275 1 payment
  10. Theratechnologies Inc. $228 10 payments
  11. Other $1,524 79 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,165 552 payments
  2. Consulting Fee $5,680 5 payments
  3. Honoraria $275 1 payment
  4. Education $78 4 payments
  5. Travel and Lodging $26 1 payment
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18 1 payment
Products named General payments · program years 2021–2025
  1. SYMTUZA $2,502 32 payments
  2. Yeztugo $2,407 4 payments
  3. Descovy $1,830 6 payments
  4. DOVATO $1,802 74 payments
  5. APRETUDE $1,169 40 payments
  6. CABENUVA $1,152 57 payments
  7. PIFELTRO $866 36 payments
  8. DELSTRIGO $781 33 payments
  9. RUKOBIA $517 24 payments
  10. ISENTRESS $385 18 payments
  11. Other $4,903 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

459

Median for Physician Assistant: 241

Drug cost

$557,894

Median for Physician Assistant: $4,110

Branded share of claims

50.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 99 $409,216
Descovy Emtricitabine/Tenofov Alafenam Brand 37 $83,384
Dovato Dolutegravir Sodium/Lamivudine Brand 13 $39,451
Ozempic Semaglutide Brand 13 $15,265
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $7,117
Valacyclovir Valacyclovir Hcl Brand 32 $752
Rosuvastatin Calcium Generic 29 $481
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $422
Atorvastatin Calcium Generic 25 $295
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 11 $208

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APRETUDE
  • ViiV Healthcare Company $494
$494 — —
CABENUVA
  • ViiV Healthcare Company $334
$334 — —
DOVATO
  • ViiV Healthcare Company $242
$242 13 —
Biktarvy
  • Gilead Sciences, Inc. $91
$91 99 —
MAVYRET
  • AbbVie, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

564 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record